Search Results

next-generation fluorescent probes—designed with precise synthetic logic—enable deeper insight into GPCR internalization GPCR Premium Membership Gives You an Edge Premium gives GPCR scientists and biotech teams a single, trusted Researchers, pharmacologists, biotech teams, and decision-makers who rely on accurate, efficient, interpretation-first

signaling platforms launched Year 4  — Pooled grants fund expansion and training programs Year 7  — International Biotech teams, CRO alliances, and academic consortia face the same challenge: how to align incentives This ecosystem design blueprint applies to biotech teams and academic consortia alike.

Kenakin Trusted insights from biotech, pharma, and academia 🎬 Plus New: Lesson Trailers   Curious about GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

His hybrid path is a model of possibility for professionals in the biotech industry who still dream of

Inês Pinheiro and Oliver Hartley from the Orion Biotechnology team on their recent study on Arylsulfatases Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640 Addex to Present at Biotech Showcase™ 2024 Establishing our first international translational research project - Institute for Protein Conference Isomorphic Labs Announces Strategic Multi-Target Research Collaboration With Novartis Salipro Biotech Meetings, and Webinars January 16 - 19, 2024 | 23rd Annual PEP Talk February 3 - 7, 2024 | SLAS2024 International

Can we leverage structural and computational insights not just to explain receptor–ligand interactions The “Predict, Not Explain” Ethos What sets the Carlsson lab apart is its internal rule : results must It struggles with ligand-bound conformations, GPCR–G protein complexes, and receptor–peptide interactions Translational Impact for Drug Discovery While the Carlsson lab is rooted in academia, its impact extends into biotech

🔹 Spot the opportunity → Why Catalio is betting big when others pull back Amid biotech slowdowns

. 👉 In biotech, where cycles are long and feedback is slow, this gap becomes even more pronounced. this clarity, everything feels important, and nothing moves decisively. 2️⃣ How will it be defined internally Biotech teams operate across disciplines, timelines, and incentives. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not

Explore this week’s research, tools, and biotech insights in one place.

Did you know that each month we collect the most recent #GPCR publications and the newest Biotech/Pharma

School of Medicine to Receive $3-Million Award from ARPA-H’s Sprint for Women’s Health Nxera Pharma Wins Biotech Year and Financing Deal of the Year at the Citeline Japan Awards 2024 GPCR therapies: Eight promising biotechs

(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company

At this international meeting, leaders shared next-gen strategies shaping modern drug discovery: Prof productive lab—it accelerated outcomes and laid the cultural foundation for the next generation of biotech insights from major conferences, emerging research, and expert commentary Whether you’re a pharmacologist, biotech

); selectivity frameworks for β₂ vs β₁ adrenergic receptors tp structural insights into cholesterol interactions binding to functional sites, live-cell compatibility, and higher specificity enable real-time tracking of interactions , internalization, and biased signaling—without fixation or permeabilization. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Explore this week’s research, tools, and biotech insights in one place.

Explore this week’s research, tools, and biotech insights in one place. The insights are ready.

Kenakin revealed  practical ways to anticipate these system-level interactions before they appear as Allosteric modulators interact with the system already in motion, shaping the receptor’s behavior without Enzyme Behavior: The Nonlinear Gatekeeper In GPCR programs, CYP interactions often appear late—usually It equips pharmacologists, discovery teams, and biotech leaders to see around mechanistic corners, recognize

insights from major conferences, emerging research, and expert commentary Whether you’re a pharmacologist, biotech GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

Premium Sneak Peak:  Human Substance P–NK1R interactions observed by NMR; Endocrine Metabolic GPCRs 2026 In Episode 3 of 3  of our series with Celtarys Research , leaders from academia and biotech unpack what

The Boston biotech revealed Wednesday afternoon that it would downsize its research to focus on its lead

Receptor Design and Synthesis of Novel GPR139 Agonists with Therapeutic Effects in Mouse Models of Social Interaction Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated ß2-Adrenergic Receptor Autoantibodies-An Interim Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023 Salipro Biotech Conference November 20 - 23, 2023 | ASCEPT Annual Scientific Meeting February 3 - 7, 2024 | SLAS2024 International

pathway of opioid drugs into cellular structures Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics attended the Swiss Biotech Day Sosei Heptares presented

Pairaudeau, CTO of Exscientia discuss transforming drug discovery using their AI-driven platform Salipro Biotech I-GPCRNet (October 25 - 27, 2023) GPCR Retreat (November 2 - 4, 2023) Structure, Mechanism, and Drug Interactions

Plus: must-read chemokine and PTH1R papers, and new momentum across biotech—from Superluminal to Neurocrine

January 2022 "G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers

fruitful research space has led to more than 700 approved drugs over previous decades—but the two-year-old biotech

Since then, Celniker has helped usher in an additional fund and headed a few startups as interim CEO. That money has gone to some 60 biotechs, much of it as early funding."

spots in your drug evaluation process, moving beyond simple potency measures to understand the dynamic interactions GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced

Our partner, Domain Therapeutics, will attend the SACHS 23rd annual biotech event in Europe. Dr. Therapeutics CEO Pascal Neuville to Discuss Game-Changing GPCR-Targeting Immunotherapies at Sachs Associates' Biotech Conference November 20 - 23, 2023 | ASCEPT Annual Scientific Meeting February 3 - 7, 2024 | SLAS2024 International